OncoMatch/Clinical Trials/NCT06074692
PARP Inhibition, Stereotactic Body Radiotherapy and Immunotherapy for Metastatic or Advanced Sarcoma (PRIMA)
Is NCT06074692 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Camrelizumab and fluzoparib with concurrent stereotactic body radiotherapy (SBRT) for sarcoma.
Treatment: Camrelizumab and fluzoparib with concurrent stereotactic body radiotherapy (SBRT) — The aim of this study is to evaluate the efficacy and safety of PARP Inhibition and programmed cell death protein-1 (PD-1) blockade immunotherapy with concurrent stereotactic body radiotherapy (SBRT) for metastatic or advanced bone and soft tissue sarcoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Sarcoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: PARP inhibitor
have not received prior PARP inhibitor treatment
Cannot have received: anti-PD-1 therapy
Exception: unless no secondary resistance
Previously received the following therapies: anti-PD-1, anti-PD-L1, or anti-PD-L2 drugs or drugs targeting another stimulating or synergistic inhibition of T cell receptors (e.g., CTLA-4, OX-40, CD137) drug and secondary resistance to the drug (i.e., the best efficacy evaluation is CR, PR or SD lasting more than 4 months, but secondary tumor resistance develops after treatment).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify